Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
An independent monitoring committee found the study unlikely to show sufficient efficacy, while Sanofi said no safety signals were identified.
9 Articles
9 Articles
Sanofi decided to stop a clinical trial of his experimental drug in the treatment of a rare neurological condition, while the study was in phase 3, the last step before a marketing request. This setback is far from being the first for the pharmaceutical group in recent months.
Sanofi ends Phase 3 riliprubart trial after weak interim results - Regional Media News
June 10 (Reuters) - Biopharmaceutical company Sanofi will stop a Phase 3 trial of its drug riliprubart for a rare neurological condition after an interim analysis of the study found it unlikely to provide sufficient efficacy. In the MOBILIZE study, the drug was being tested for chronic inflammatory demyelinating polyneuropathy in patients whose condition resisted standard treatments. • An independent data monitoring committee found no safety iss…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
